MA29804B1 - Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques - Google Patents
Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiquesInfo
- Publication number
- MA29804B1 MA29804B1 MA30780A MA30780A MA29804B1 MA 29804 B1 MA29804 B1 MA 29804B1 MA 30780 A MA30780 A MA 30780A MA 30780 A MA30780 A MA 30780A MA 29804 B1 MA29804 B1 MA 29804B1
- Authority
- MA
- Morocco
- Prior art keywords
- phenyl
- processes
- pyridyl
- disorders
- preparation
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- -1 PHENYL-PHENYL-1,2,4-OXADIAZOLONE DERIVATIVES Chemical class 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004129 fatty acid metabolism Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021235 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29804B1 true MA29804B1 (fr) | 2008-09-01 |
Family
ID=35809809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30780A MA29804B1 (fr) | 2005-09-29 | 2008-03-24 | Derives de phenyl-et pyridyl-1,2,4-oxadiazolone renfermant un groupe phenyle, procedes pour leur preparation et leur utilisation en tant qu'agents pharmaceutiques |
| MA30783A MA29807B1 (fr) | 2005-09-29 | 2008-03-24 | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30783A MA29807B1 (fr) | 2005-09-29 | 2008-03-24 | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US7834030B2 (enExample) |
| EP (2) | EP1934206B1 (enExample) |
| JP (2) | JP5183479B2 (enExample) |
| KR (2) | KR20080048520A (enExample) |
| CN (2) | CN101273036A (enExample) |
| AR (2) | AR056541A1 (enExample) |
| AT (1) | ATE537167T1 (enExample) |
| AU (2) | AU2006299092A1 (enExample) |
| BR (2) | BRPI0616465A2 (enExample) |
| CA (2) | CA2624093A1 (enExample) |
| CR (1) | CR9784A (enExample) |
| CY (1) | CY1113376T1 (enExample) |
| DK (1) | DK1931660T3 (enExample) |
| DO (2) | DOP2006000204A (enExample) |
| EC (1) | ECSP088323A (enExample) |
| ES (1) | ES2392181T3 (enExample) |
| IL (2) | IL190227A (enExample) |
| MA (2) | MA29804B1 (enExample) |
| MY (2) | MY148982A (enExample) |
| NO (2) | NO20081367L (enExample) |
| NZ (2) | NZ566878A (enExample) |
| PE (2) | PE20070545A1 (enExample) |
| PL (1) | PL1931660T3 (enExample) |
| PT (1) | PT1931660E (enExample) |
| RU (2) | RU2008112201A (enExample) |
| SI (1) | SI1931660T1 (enExample) |
| TN (1) | TNSN08145A1 (enExample) |
| TW (2) | TW200811154A (enExample) |
| UY (2) | UY29830A1 (enExample) |
| WO (2) | WO2007039172A1 (enExample) |
| ZA (1) | ZA200801630B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| SI2074123T1 (sl) | 2006-10-16 | 2013-03-29 | Bionomics Limited | Nove anksiolitične spojine |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| US10793515B2 (en) * | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| US20210130285A1 (en) * | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2012116415A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1200824A1 (en) * | 2012-01-18 | 2015-08-14 | Daiichi Sankyo Company, Limited | Substituted phenylazole derivative |
| BR112014030412A2 (pt) | 2012-06-14 | 2017-06-27 | Basf Se | método para combater ou controlar pragas, método para proteger culturas, compostos, processo para a preparação de compostos, uso de um composto, composição agrícola ou veterinária e semente. |
| US10258672B2 (en) | 2014-10-09 | 2019-04-16 | Case Western Reserve University | Compositions and methods of treating root avulsion injury |
| CN106616029B (zh) * | 2016-12-08 | 2020-05-01 | 西南大学 | 一种提高虹鳟抗病能力的饲料添加剂及其制备方法 |
| CN108976150B (zh) * | 2017-06-05 | 2022-11-18 | 重庆博腾制药科技股份有限公司 | 一种3-乙基-4-氟苯腈的制备方法 |
| AU2018301399B2 (en) * | 2017-07-11 | 2024-08-29 | Case Western Reserve University | Compositions and methods for treating myelin disorders |
| BR112021002207A2 (pt) | 2018-08-10 | 2021-05-04 | Diapin Therapeutics, Llc | tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios |
| WO2021092279A1 (en) * | 2019-11-06 | 2021-05-14 | Board Of Regents, The University Of Texas System | Methods for the treatment of dysmyelinating/demyelinating diseases |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025237291A1 (zh) * | 2024-05-13 | 2025-11-20 | 上海翰森生物医药科技有限公司 | 一种异丙基异喹啉类化合物的制备方法及其中间体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783593A (en) | 1993-11-04 | 1998-07-21 | Abbott Laboratories | Inhibitors of squalene synthetase and protein farnesyltransferase |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| US6380191B1 (en) * | 1999-06-18 | 2002-04-30 | Merck & Co. Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DE10112768A1 (de) | 2001-03-16 | 2002-09-19 | Merck Patent Gmbh | Phenylderivate 3 |
| GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
| WO2003016291A1 (en) * | 2001-08-10 | 2003-02-27 | Nippon Chemiphar Co., Ltd. | ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ |
| WO2003072100A1 (en) * | 2002-02-25 | 2003-09-04 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| JPWO2004080943A1 (ja) | 2003-03-11 | 2006-06-08 | 小野薬品工業株式会社 | シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤 |
| WO2005054213A1 (ja) | 2003-12-02 | 2005-06-16 | Shionogi & Co., Ltd. | ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体 |
| CN100516065C (zh) * | 2004-04-01 | 2009-07-22 | 安万特药物公司 | 1,3,4-二唑-2-酮作为PPAR-δ调节剂 |
| EP1586573B1 (en) * | 2004-04-01 | 2007-02-07 | Sanofi-Aventis Deutschland GmbH | Oxadiazolones, processes for their preparation and their use as pharmaceuticals |
-
2006
- 2006-09-26 BR BRPI0616465-0A patent/BRPI0616465A2/pt not_active Application Discontinuation
- 2006-09-26 WO PCT/EP2006/009298 patent/WO2007039172A1/en not_active Ceased
- 2006-09-26 AU AU2006299092A patent/AU2006299092A1/en not_active Abandoned
- 2006-09-26 SI SI200631453T patent/SI1931660T1/sl unknown
- 2006-09-26 EP EP06805857A patent/EP1934206B1/en active Active
- 2006-09-26 KR KR1020087007735A patent/KR20080048520A/ko not_active Withdrawn
- 2006-09-26 KR KR1020087007148A patent/KR101342415B1/ko not_active Expired - Fee Related
- 2006-09-26 CA CA002624093A patent/CA2624093A1/en not_active Abandoned
- 2006-09-26 EP EP06792252A patent/EP1931660B1/en active Active
- 2006-09-26 AU AU2006299086A patent/AU2006299086A1/en not_active Abandoned
- 2006-09-26 PL PL06792252T patent/PL1931660T3/pl unknown
- 2006-09-26 JP JP2008532648A patent/JP5183479B2/ja not_active Expired - Fee Related
- 2006-09-26 CN CNA2006800359450A patent/CN101273036A/zh active Pending
- 2006-09-26 CN CNA2006800344489A patent/CN101268069A/zh active Pending
- 2006-09-26 JP JP2008532645A patent/JP2009509986A/ja not_active Abandoned
- 2006-09-26 PT PT06792252T patent/PT1931660E/pt unknown
- 2006-09-26 WO PCT/EP2006/009304 patent/WO2007039178A2/en not_active Ceased
- 2006-09-26 BR BRPI0616457-9A patent/BRPI0616457A2/pt not_active IP Right Cessation
- 2006-09-26 RU RU2008112201/04A patent/RU2008112201A/ru not_active Application Discontinuation
- 2006-09-26 AT AT06805857T patent/ATE537167T1/de active
- 2006-09-26 NZ NZ566878A patent/NZ566878A/en not_active IP Right Cessation
- 2006-09-26 CA CA2624105A patent/CA2624105C/en not_active Expired - Fee Related
- 2006-09-26 RU RU2008112202/04A patent/RU2008112202A/ru not_active Application Discontinuation
- 2006-09-26 NZ NZ566875A patent/NZ566875A/en not_active IP Right Cessation
- 2006-09-26 DK DK06792252.6T patent/DK1931660T3/da active
- 2006-09-26 ES ES06792252T patent/ES2392181T3/es active Active
- 2006-09-27 TW TW095135657A patent/TW200811154A/zh unknown
- 2006-09-27 AR ARP060104222A patent/AR056541A1/es not_active Application Discontinuation
- 2006-09-27 DO DO2006000204A patent/DOP2006000204A/es unknown
- 2006-09-27 MY MYPI20064224A patent/MY148982A/en unknown
- 2006-09-27 MY MYPI20064223A patent/MY149182A/en unknown
- 2006-09-27 TW TW095135660A patent/TWI398436B/zh not_active IP Right Cessation
- 2006-09-27 DO DO2006000205A patent/DOP2006000205A/es unknown
- 2006-09-27 AR ARP060104225A patent/AR056203A1/es not_active Application Discontinuation
- 2006-09-28 PE PE2006001178A patent/PE20070545A1/es not_active Application Discontinuation
- 2006-09-29 PE PE2006001189A patent/PE20070768A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29830A patent/UY29830A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29829A patent/UY29829A1/es not_active Application Discontinuation
-
2008
- 2008-02-19 ZA ZA2008/01630A patent/ZA200801630B/en unknown
- 2008-02-29 CR CR9784A patent/CR9784A/es not_active Application Discontinuation
- 2008-03-14 NO NO20081367A patent/NO20081367L/no not_active Application Discontinuation
- 2008-03-14 NO NO20081370A patent/NO20081370L/no not_active Application Discontinuation
- 2008-03-17 IL IL190227A patent/IL190227A/en not_active IP Right Cessation
- 2008-03-17 IL IL190228A patent/IL190228A0/en unknown
- 2008-03-24 MA MA30780A patent/MA29804B1/fr unknown
- 2008-03-24 MA MA30783A patent/MA29807B1/fr unknown
- 2008-03-26 US US12/055,764 patent/US7834030B2/en not_active Expired - Fee Related
- 2008-03-26 US US12/055,793 patent/US20080287409A1/en not_active Abandoned
- 2008-03-27 EC EC2008008323A patent/ECSP088323A/es unknown
- 2008-03-28 TN TNP2008000145A patent/TNSN08145A1/en unknown
-
2009
- 2009-05-29 US US12/474,838 patent/US7851493B2/en not_active Expired - Fee Related
-
2012
- 2012-10-31 CY CY20121101040T patent/CY1113376T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
| MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| MA29807B1 (fr) | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. | |
| JOP20210307A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
| MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
| MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| MX2010006647A (es) | Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos. | |
| MA31857B1 (fr) | N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci | |
| MA27676A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA35875B1 (fr) | Dérivés d'aza-adamantane et leurs utilisations | |
| MA29812B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides cycliques, procedes pour leur preparation et leur utilisation en tant que substances pharmaceutiques | |
| MA27736A1 (fr) | Dérivés de l'acide 3-méthyl-2-(3-(2-phényloxazol-4-ylméthoxy)cyclohexanecarbonylaminobutyrique et composés apparentés utilisés comme modulateurs de PPAR destinés au traitement du diabète de type 2 et de l'artériosclérose | |
| MA29811B1 (fr) | [1,3,4]-thiadiazol-2-yl-amides d'acide (aryle bicyclique)-sulfonique procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| MA29793B1 (fr) | Derives d'imidazole pour le traitement de troubles neurologiques. | |
| MA29806B1 (fr) | Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| JP6810983B2 (ja) | （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物 | |
| MA27738A1 (fr) | Dérivés de cycloalkyle 1,3-substitués contenant des groupes acides, principalement hétérocycliques, procédés de préparation correspondants et utilisation desdits dérivés en tant que médicaments | |
| CA3181302A1 (en) | Rigid cannabidiol analogues as potent modulators of cannabinoid receptors and uses thereof | |
| WO2007042544A3 (en) | Imidazole derivatives and their use for modulating the gabaa receptor complex | |
| MA27740A1 (fr) | Dérivés arylcycloalkylés comportant des chaines latérales ramifiées servant de modulateurs du récepteur PPAR, procédé pour les préparer, et leur utilisation en tant que médicaments |